NCT07148414Active, not recruitingPhase 2
A Study of SPY072 in Rheumatic Disease
Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 285 (estimated)
- First submitted
- 21 Aug 2025
- Start date
- 21 Aug 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Spyre Therapeutics, Inc.
- NCT number
- NCT07148414
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 285
- From 21 Aug 2025 to the primary completion date, 31 Oct 2026
- 64 sites in 8 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other autoimmune, rheumatologic, inflammatory diseases or pain-amplification syndromes that might confound the evaluations of efficacy of SPY072
Other
- Inadequate response to \>2 classes of bDMARDs/tsDMARDs
Who the study is looking for
- For rheumatoid arthritis:
- Moderate-to-severely active RA as defined by the presence of ≥4 swollen joints (based on 28 joint count) and ≥4 tender joints (based on 28 joint count) at Screening and Day 1.
- Documentation of ≥1 of the following:
- Positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at Screening, OR
- Radiology report documenting bony erosions in hands or feet consistent with RA on previous radiographs
- Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:
- ≥1 csDMARD treatment; AND/OR
- ≤2 classes of bDMARD/tsDMARD treatment (\>2 classes of bDMARDs and/or tsDMARDs is exclusionary)
- For axial spondyloarthritis:
- Moderate-to-severely active axSpA defined by BOTH of the following at Screening AND Day 1:
- BASDAI ≥4, AND
- Back pain ≥4 (from BASDAI Item 2)
- hsCRP greater than the ULN per the central laboratory at Screening
- Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:
- 2 different NSAIDs given at the maximum tolerated dose for ≥4 weeks or intolerant to or has a contraindication to NSAID therapy; AND/OR
- ≤2 classes of bDMARD (anti-TNF or anti-IL-17)/tsDMARD at an approved dose for ≥12 weeks (\>2 classes of bDMARDs/tsDMARDs is exclusionary)
- For psoriatic arthritis:
- Screening and Day 1 TJC ≥3 out of 68 and SJC ≥3 out of 66 (dactylitis counts as 1 joint each)
- ≥1 active plaque psoriasis lesion and/or a documented history of psoriasis
- Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:
- ≥1 NSAID treatment; AND
- ≥1 csDMARD treatment; AND/OR ≤2 classes of bDMARD/tsDMARD treatment (\>2 classes of bDMARDs and/or tsDMARDs is exclusionary)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (64)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.